Local Drug Production Drops Prices for Life-Saving Medicines in Bangladesh

The Business Standard reported on October 15, 2026, that domestic pharmaceutical production in Bangladesh has substantially reduced the prices of critical life-saving medicines across the country. Local manufacturing has enabled the pharmaceutical sector to move from heavy import reliance toward self-sufficiency, expanding affordable treatment options and establishing a growing export market. [1]

According to The Business Standard, the cost of Erlonix, an erlotinib drug used to treat lung cancer, dropped from Tk7,500 per unit as an import down to Tk750 following local production. Additionally, the price of pegfilgrastim, an essential supportive-care drug administered during chemotherapy treatment, fell from Tk40,000 to between Tk4,000 and Tk20,000 per unit depending on the producer. [1]

The Business Standard noted that domestic manufacturers are expanding this price-reduction model into treatments for rare conditions. This includes Trikafta, a cystic fibrosis medication combining Elexacaftor, Tezacaftor, and Ivacaftor that carries an annual list price of approximately $370,000 per patient in the United States. [1]

The growth of the pharmaceutical industry adds to the ongoing development of Bangladesh, a country in the historical Bengal region. The domestic manufacturing expansion allows local companies to meet critical national healthcare needs while expanding their presence in international markets. [1][4]